<DOC>
	<DOCNO>NCT01781468</DOCNO>
	<brief_summary>This randomized phase III trial study armodafinil see well work reduce cancer-related fatigue patient high grade glioma . Armodafinil may help relieve fatigue patient high grade glioma .</brief_summary>
	<brief_title>Armodafinil Reducing Cancer-Related Fatigue Patients With High Grade Glioma</brief_title>
	<detailed_description>Patients experience fatigue related cancer ask take part study . Cancer-related fatigue common symptom patient cancer . Patients receive armodafinil placebo . Please see `` Arms '' section detail regard treatment assignment . The primary objective study determine preliminary efficacy measure patient report fatigue Brief Fatigue Inventory ( BFI ) 8 week two dos ( 150 mg 250 mg ) armodafinil treat moderate fatigue compare placebo patient high grade glioma . The secondary objective study list . 1 . To evaluate tolerability 8 week 150 mg 250 mg armodafinil patient population . 2 . To assess effect armodafinil 8 week cognitive function patient high grade glioma . 3 . To assess impact armodafinil global quality life fatigue endpoint patient population high grade glioma . 4 . Explore correlation BFI , Patient-Reported Outcomes Measurement Information System ( PROMIS ) , Patient-Reported Outcomes version Common Terminology Criteria Adverse Events ( PRO-CTCAE ) measure , well , relationship fatigue cognitive difficulty . Patients receive armodafinil placebo total 8 week .</detailed_description>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>Age ≥ 18 year Diagnosed glioblastoma , gliosarcoma , small cell large cell glioblastoma , glioblastoma oligo feature , glioblastoma primitive neuroectodermal tumorlike component ( GBMPNET ) feature , anaplastic astrocytoma , anaplastic oligodendroglioma , anaplastic oligoastrocytoma clinically stable complete radiation therapy &gt; 21 day ≤ 24 month prior enrollment . NOTE : Clinical stability define stable improved Karnofsky Performance Status ( KPS ) compare prior month . ≥ 6 score bad fatigue question BFI ( Brief Fatigue Inventory ) . It require patient complete entire BFI meet criterion . Undergone surgery ( gross total subtotal resection ) biopsy treat concurrent radiation therapy chemotherapy standard care glioblastoma , gliosarcoma , small cell large cell glioblastoma , glioblastoma oligo feature , glioblastoma primitive neuroectodermal tumorlike component ( GBMPNET ) feature , anaplastic astrocytoma , anaplastic oligodendroglioma anaplastic oligoastrocytoma patient . NOTE : Radiation must complete per second eligibility criterion , chemotherapy allow . Negative serum pregnancy test do ≤ 7 day prior registration woman determine childbearing potential treating physician . Ability complete questionnaire ( ) assistance Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 , 1 , 2 3 Provide inform write consent Willing return enrol institution followup ( Active Monitoring Phase study ) Stable dose corticosteroid ≥ 14 day prior registration Pregnant woman , nurse woman , men woman childbearing potential unwilling employ adequate contraception since study involve investigational agent whose genotoxic , mutagenic teratogenic effect develop fetus newborn unknown . History hypersensitivity psychostimulants History steroid psychosis History currently take medication attention deficit hyperactivity disorder , severe anxiety disorder , schizophrenia , substance abuse patient record and/or self report Currently use pharmacologic agent nonpharmacologic intervention specifically treat fatigue include psychostimulants , antidepressant , acupuncture , etc . exclude . Note : antidepressant use treat item fatigue ( hot flash depression ) allow patient stable dose ≥ 30 day prior registration plan continue duration trial . Erythropoietin agent treat anemia allow . Exercise allow . Anticipating surgery , laboratory evidence hypothyroidism elevate thyroid stimulate hormone ( TSH ) concentration blood &gt; 5.0 mlU/L , profound anemia ( hemoglobin level &lt; 10 g/dL ≤ 28 day prior registration ) , clinical depression per physician discretion . Active history Tourrette 's syndrome tic disorder History active glaucoma History intractable epilepsy , uncontrolled seizure disorder Any follow comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimen : 1 . History myocardial infarction 2 . Unstable angina 3 . Left ventricular hypertrophy 4 . Mitral valve prolapse syndrome Receiving medication substance strong moderate inhibitor cytochrome P450 3A4 ( CYP3A4 ) . Use strong moderate inhibitor specify protocol prohibit ≤ 7 day prior registration . See protocol information . Receiving medication substance inducer CYP3A4 . Use inducer specify protocol prohibit ≤ 7 day prior registration . See protocol information .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>